Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed Jun 22, 2017
Insider Transaction Report
Form 4
CHAMPSI FARAH
Director
Transactions
- Award
Common Stock
2017-06-20+2,410→ 66,074 total - Award
Director Stock Option (Right to Buy)
2017-06-20+8,810→ 8,810 totalExercise: $91.21Exp: 2027-06-19→ Common Stock (8,810 underlying)
Footnotes (1)
- [F1]The stock option shall vest in 12 successive equal monthly installments following the date of grant.